Aethlon Medical (NASDAQ:AEMD) Shares Cross Below Two Hundred Day Moving Average – Here’s Why

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.37 and traded as low as $2.06. Aethlon Medical shares last traded at $2.09, with a volume of 45,935 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average target price of $560.00.

Aethlon Medical Trading Down 5.0%

The firm has a market cap of $2.03 million, a PE ratio of -0.09 and a beta of 1.60. The stock’s 50 day moving average price is $2.79 and its 200 day moving average price is $6.37.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($2.04). Analysts forecast that Aethlon Medical, Inc. will post -0.73 earnings per share for the current year.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.